SCM
CADL icon

Stonepine Capital Management’s Candel Therapeutics CADL Stock Holding History

Stonepine Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$502K Buy
+102,500
New +$558K 0.2% 58

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonepine Capital Management's CADL Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 102,500 shares worth $502K. The stake represents 0.2% of the portfolio and ranks #58 among its holdings.

114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Stonepine Capital Management held 102,500 shares of Candel Therapeutics worth $502K as of Q1 2026.
  • Candel Therapeutics was a new Stonepine Capital Management position in Q1 2026.
  • Candel Therapeutics made up 0.2% of Stonepine Capital Management's portfolio in Q1 2026, its #58 holding.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.